Skip to main content
Explore URMC
menu

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Head and Neck Cancer

Research Question:
How well does radiation therapy work with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body and who cannot take cisplatin?

Basic Study Information

Purpose:
This randomized phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab or cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.

Location: University of Rochester Medical Center
Study Reference #: RHAN18031

Lead Researcher (Principal Investigator)

Lead Researcher:  Yuhchyau Chen

Study Contact Information

Study Coordinator: Therese Smudzin
Phone: (585) 275-7848
Email: Therese_Smudzin@urmc.rochester.edu

Additional Study Details

Return to Search